Billionaire Profile
Fan Xiulian
Global Rank
#2933

Image: Public domain | via Wikimedia Commons

Fan Xiulian

CEO, Haisco Pharmaceutical Group
CN
Real-Time Net Worth
$2B
As of December 2025
Age
62
Source
Pharmaceuticals
Industry
healthcare
Citizenship
CN

Biography

Fan Xiulian is a prominent figure in the pharmaceutical industry and is the CEO of Haisco Pharmaceutical Group. As of late 2024, her estimated net worth is $2.0 billion. Her wealth stems from her self-made success in the pharmaceuticals sector. Fan co-founded the precursor to Haisco in 2000 and the company went public in 2012. Her career is marked by a strategic focus on research and development, contributing to her company's success in producing specialty pharmaceuticals, including those for anesthesia, oncology antiemetics, digestive care, antibiotics, and cardiovascular treatments. She currently holds the rank #2933 on Forbes' 2025 Billionaires list.

Wealth Over Time

In-Depth Profile

Early Life and Career

Born in Mainland China in 1963, Fan Xiulian's early life laid the foundation for her future success. She graduated from Guangzhou's South China University of Technology. Fan's career began with establishing a presence in the pharmaceuticals industry. She co-founded the precursor to Haisco Pharmaceutical Group in 2000, along with Wang Junmin and Zheng Wei. The company's focus was on developing, producing, and selling chemical drug preparations and bulk drugs.

Rise to Success

In 2012, Haisco Pharmaceutical Group went public on the Shenzhen Stock Exchange. This move significantly boosted Fan's net worth. As the company's shares increased in value, so did her wealth. She owns a significant stake in Haisco, contributing to her status as a billionaire. She was appointed as the vice chairperson of Haisco in 2007. Later, in 2013, Forbes listed Fan as a billionaire, marking a significant milestone in her career.

Key Business Strategies

Haisco Pharmaceutical Group's success is attributed to several key strategies. A strong emphasis on research and development (R&D) helped the company expand its product line. This focus on innovation allowed Haisco to introduce new pharmaceutical products to the market. The company also strategically invested in production facilities to boost the output of high-growth drug products. The company's strong performance and the growing demand for pharmaceuticals in China fueled its growth.

Philanthropy

Fan Xiulian has demonstrated a commitment to philanthropy through contributions to local communities and other initiatives.

Career Milestones

2000

Co-founded Haisco Pharmaceutical Group

Co-founded the precursor to Haisco with Wang Junmin.

2007

Appointed Vice Chairperson of Haisco

Assumed the role of Vice Chairperson at Haisco Pharmaceutical Group.

2012

Haisco IPO

Haisco Pharmaceutical Group went public on the Shenzhen Stock Exchange.

Philanthropy & Social Impact

Community Support

Yalong Cultural Festival

$0.5M

Donated to the Yalong Cultural Festival in the Himalayan province

Business Philosophy & Leadership

Notable Quotes

"“Our goal is to help Chinese enjoy the same high-quality global pharmaceutical products and treatment available worldwide.”"

Leadership Principles

Focus on Innovation

Prioritizing the development and introduction of new pharmaceutical products.

Strategic Investment

Investing in production and R&D for sustained growth.

Controversies & Challenges

2008

Stake Transfer

Transferred her shares in Haisco to her mother, later reclaiming them during the global financial crisis.